Company intelligence / Profile preview

Sonio

Paris, Île-de-France, Francesonio.ai ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Sonio has developed and commercialized AI-powered software solutions to assist practitioners during prenatal ultrasound examinations. Their products help detect and diagnose fetal anomalies—including rare genetic conditions—by combining patient history, imaging data, and real-time practitioner input. Over 250 healthcare professionals use their solutions globally. Their technology is CE marked (Europe) since May 2021 and FDA approved since 2022.

Therapeutic areas: Rare Diseases
Modalities: DeviceSoftware (AI-enabled clinical decision support)
Industry: Medical Imaging

Partnerships

Samsung France (women’s health ultrasound hardware)Lifecell (India), Manager Systems (Brazil), Dynamic Medicals (Nigeria)—specialized distributorsAcademic partners including Hopital Necker (Paris)

Beyond the preview

Go deeper on Sonio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sonio.

Explore the full profile